Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

Here are some of the advancements that will shape the future of heart care in 2025: ...

Pi-Cardia today announced the first commercial procedures with its ShortCut leaflet modification device for enabling heart ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this year.

The UHS Heart & Vascular Institute recently celebrated a significant milestone with the completion of their 1,000th TAVR (Transcatheter Aortic Valve Replacement) procedure. This achievement is ...

Cardiac care leaps forward Dr Milan Chag, senior interventional cardiologist at CIMS Hospital, explained, “With advancements ...

First dedicated leaflet modification solution to enable TAVR in patients at risk of coronary obstruction.

The Society for Cardiovascular Angiography & Interventions (SCAI) has published an expert consensus statement that provides interventional cardiologists, cardiothoracic surgeons, and heart teams with ...

Minimally invasive heart procedures like transcatheter aortic valve replacement (TAVR) and MitraClip placement to treat mitral regurgitation can improve quality of life, and even be lifesaving, for ...

Pete Furnbaugh: First of all, the Tavr procedure. We’re at how many procedures now that you’ve done? Dr. Tristan Smith: So, here we’ve done close to 225. Before this, where we were before ...

Zovighian said the transition to CEO has been relatively smooth since he joined Edwards in 2015 and spent eight years in ...